PROX: Primary resistance to oxaliplatin containing regimen in the first line treatment of metastatic colorectal carcinoma—Retrospective analysis.

Larissa Machado,Tiago Felismino,Diogo De Brito Sales,Diogo Morbeck,Amanda Karani,Lara Azevedo Diniz,Ingrid Hariman Fonseca Cunha,Virgilio Souza,Maria Dirlei Begnami,Mariana Petaccia de Macedo,Dirce Maria Carraro,Celso Lopes Mello

PROX: Primary resistance to oxaliplatin containing regimen in the first line treatment of metastatic colorectal carcinoma—Retrospective analysis.

2018

Larissa Machado
Tiago Felismino
Diogo De Brito Sales
Diogo Morbeck
Amanda Karani
Lara Azevedo Diniz
Ingrid Hariman Fonseca Cunha
Virgilio Souza
Maria Dirlei Begnami
Mariana Petaccia de Macedo
Dirce Maria Carraro
Celso Lopes Mello

855Background: The rate of primary resistance to modern first line (FL) chemotherapy regimen in the treatment of metastatic colorectal cancer (mCRC) is low. Progression Disease (PD) to FOLFOX in th...

Keywords:

PROX
Cancer research
Pathology
Colorectal cancer
Oxaliplatin
Regimen
Medicine
retrospective analysis
Oncology
Internal medicine
Chemotherapy regimen
FOLFOX
Disease
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations